Geniko Nosokomeio Thessalonikis George Papanikolaou
- Address
- lock Available on a paid plan
Respiratory Research
The Respiratory Tract Diseases program at Geniko Nosokomeio Thessalonikis George Papanikolaou focuses on improving care for conditions such as asthma, chronic obstructive pulmonary disease, bronchiectasis, idiopathic pulmonary fibrosis, and pulmonary sarcoidosis.
- Severe asthma with eosinophilic phenotype
- Progression of chronic obstructive pulmonary disease
- Bronchiectasis with chronic Pseudomonas infection
- Therapeutic evaluation in idiopathic pulmonary fibrosis
- Imaging studies for active pulmonary sarcoidosis
Trials test novel inhaled agents, biologic therapies, and advanced diagnostics to reduce exacerbations and improve lung function.
Lung Cancer Clinical Trials
Research on Non‑Small Cell Lung Cancer and small‑cell lung cancer aims to expand treatment options through targeted therapies, immunotherapy combinations, and adjuvant strategies after surgery.
- EGFR‑mutated NSCLC targeted agents
- KRAS G12C inhibitor versus chemotherapy
- PD‑L1 high NSCLC immunotherapy combos
- Adjuvant pembrolizumab post‑resection
- Bronchoscopic diagnostic advancements
The goal is to increase survival rates and assess safety of emerging drugs in advanced and early‑stage lung cancer.
Hematology & Transplant Research
The department investigates Acute Myeloid Leukemia, Multiple Myeloma, Myelofibrosis and related stem‑cell transplant complications, exploring cellular and targeted treatments.
- CAR‑T cell therapy for relapsed myeloma
- JAK inhibitor plus ruxolitinib in myelofibrosis
- Graft‑versus‑host disease prevention after HSCT
- Targeted agents for acute leukemias
- Novel regimens for mantle‑cell lymphoma
Studies seek to improve response durability and reduce transplant‑related toxicity.
Renal & Vascular Immunology
Investigations into IgA nephropathy, Complement inhibition, and Atypical hemolytic uremic syndrome address proteinuria reduction and kidney protection.
- Ravulizumab for IgAN kidney function preservation
- Iptacopan in immune‑complex membranoproliferative GN
- Finerenone to slow CKD progression
- MK‑2060 for arteriovenous graft thrombosis prevention
- Complement blockade in paroxysmal nocturnal hemoglobinuria
The aim is to lower proteinuria, protect renal function, and improve vascular outcomes in high‑risk patients.
Cardiovascular & Metabolic Studies
Programs targeting Arterial Hypertension, Heart failure with preserved ejection fraction, and Type 2 diabetes evaluate new drug combinations and inflammatory pathways.
- Fixed‑dose irbesartan/amlodipine efficacy
- Finerenone added to standard of care
- Inflammatory biomarkers in CKD with hypertension
- Triple bronchodilator therapy impact on cardiopulmonary outcomes in COPD
- Atherosclerotic disease management in end‑stage kidney disease
These trials aim to reduce cardiovascular events, improve blood pressure control, and mitigate renal inflammation.
Mental Health & Neurological Research
The site also supports studies on Major Depressive Disorder, Schizophrenia, and seizure disorders, focusing on symptom relief and disease mechanisms.
- Iclepertin safety in schizophrenia
- Adjunctive therapy for treatment‑resistant depression
- Anti‑IL‑33 antibody for seizure reduction
- Neuroimaging biomarkers in pulmonary sarcoidosis affecting CNS
- Cognitive outcomes in chronic inflammatory disease
Objectives include improving quality of life, evaluating novel psychopharmacologic agents, and understanding neuro‑immune interactions.
Site Overview
Activity Indicator
Last 6 months
Trial Flow
How this site's trials are distributed across therapeutic areas and active substances (IMPs), and how they're positioned within their overall lifecycle status. Flow thickness represents the number of unique trials.
Top 4 of 17 therapeutic areas and 15 of 228 IMPs, ranked by number of trials.
Compounds & Molecules Timeline
The time span of clinical-trial activity for the main active substances (IMPs) studied at this site over the last 8 years. Each bar runs from the earliest trial start to the most recent end; a substance with a trial still open has no recorded end and is shown as ongoing.
Top 40 of 224 compounds, ranked by number of trials.
Sponsor & Partnership
Top sponsors by active trials, and the ones that have come back for more than one study.
Sponsor Network
Top 44 by active trials.
- 1AstraZeneca AB9active
lock +43 more on a paid plan
Partnership History
Sponsors with repeated collaboration (≥ 2 trials).
- 1AstraZeneca AB15trials
lock +24 more on a paid plan
Sponsor Network Graph
How sponsors and therapeutic areas connect across this site's active trials: each link is at least one active trial shared between them, and bigger nodes mean more activity. Click a node to see its exact connections.
Country Benchmark
Compared to 173 other sites in Greece
Therapeutic Area Benchmark — Greece
Select a therapeutic area to compare against other sites in Greece.
Competitor Comparison
Similar sites in the same country running a comparable number of trials (within ±30%), scored on how closely their trial portfolios match this one. Higher percentages mean a more similar profile.
Country: Greece
Market Share
Country: Greece
Therapeutic Area Market Share
Select a therapeutic area to view its disease coverage breakdown.
Heat Maps & Advanced Analytics
How often specific conditions appear in trials across this site and comparable sites from the same country. Each row is a site, each column a condition, and each cell the number of trials on it — darker means more activity.
Other Trials in Geniko Nosokomeio Thessalonikis George Papanikolaou
lock Showing 1 of 164 trials — the rest is available on a paid plan.
| Trial | Sponsor | Phase | Status | Start Date | End Date |
|---|---|---|---|---|---|
| A multicenter, randomized, double-blind, parallel group, placebo-controlled study to evaluate the efficacy and safety of iptacopan (LNP023) in idiopathic immune complex mediated membranoproliferative glomerulonephritis (IC-MPGN) | Novartis Pharma AG | Phase III | Recruiting | Oct 2023 | — |
IMP list
lock Showing 1 of 228 compounds — the rest is available on a paid plan.
| IMP | Trials | Status | First start | Last start |
|---|---|---|---|---|
| Dexamethasone | 15 | Unknown | 2017-12-14 | 2026-06-12 |
Upgrade this site to Business Plan
Own the profile, publish your feasibility data and reach sponsors directly.
Is something out of date?
Tell us what needs correcting and we'll update this profile.
lock Available to Business plan sites only.